Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, LiFraumeni syndrome and Cowden syndrome
Robays J, Stordeur S, Hulstaert F, van Maerken T, Claes K, Janin N, Matthijs G, 't Kint de Roodenbeke D, Berlière M, Wildiers H, Poppe B
Record ID 32015000837
English
Authors' objectives:
This guideline provides recommendations based on current scientific evidence for the diagnosis and follow-up of persons at increased familial risk for breast and/or ovarian cancer. Clinicians are encouraged to interpret
these recommendations in the context of the individual person situation, values and preferences.
The guidelines are based on clinical evidence and may not always be in line with the current criteria for NIHDI (RIZIV/INAMI) reimbursement of diagnostic and therapeutic interventions. The NIHDI may consider adaptation of reimbursement/funding criteria based on these guidelines.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://kce.fgov.be/sites/default/files/page_documents/KCE_236_oncogenetic%20testing_Report.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Belgium
MeSH Terms
- Humans
- Medical Oncology
- Biomarkers, Tumor
- Ovarian Neoplasms
- Breast Neoplasms
- Hamartoma Syndrome, Multiple
- Neoplasms
- Li-Fraumeni Syndrome
- Genetic Predisposition to Disease
Contact
Organisation Name:
Belgian Health Care Knowledge Centre
Contact Address:
Administrative Centre Botanique, Doorbuilding (10th floor), Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium tel: +32 2 287 33 88 fax: +32 2 287 33 85
Contact Name:
info@kce.fgov.be
Contact Email:
info@kce.fgov.be
Copyright:
Belgian Health Care Knowledge Centre (KCE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.